Study design (if review, criteria of inclusion for studies)
Controlled: Yes.1 Randomised: Yes.2 Open: No.3 Single blind: No.4 Double blind: Yes.5 Parallel group: Yes.6 Cross over: No
Participants
Principal inclusion criteria: 1. Male and female subjects 18 to 65 years of age (inclusive), on the day of signing informed consent; Stable pulmonary symptoms associated with CF for 28 days prior to Screening
Interventions
multiple ascending doses (MAD) of inhaled SNSP113 administered once-daily for 28 days to adult Cystic Fibrosis (CF) subjects.
Outcome measures
Primary end point(s): ⢠Vital signs (blood pressure, heart rate, respiratory rate) ⢠Clinical laboratory evaluations (hematology included complete blood cell count (CBC) with differential and platelet count, serum biochemistry including blood urea nitrogen and creatinine, liver function tests, coagulation profile, and urinalysis) ⢠ECG parameters ⢠Pulmonary function assessed by spirometry, pulse oximetry ⢠PE
Related topics
Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis
Antibiotic treatment of early pseudomonas aeruginosa
Antibiotics for pulmonary exacerbations
Inhaled antibiotics in cystic fibrosis
Prophylactic use of oral antistaphylococcal antibiotic
Scheduled antibiotics every 3-4 months / symptom-based treatment